Positions 51–62 of 62.
Something I keep coming back to: glucagon is the most under-discussed thing on this board. Imaging-derived liver fat fraction is a surrogate. It correlates with…
small win: glucagon stopped being a problem at week 36. This is a description of what happened to me and not a plan for anybody else. The endpoint vocabulary, because…
someone explain survodutide to me like I have not read a paper in years. I am not trying to be the "source?" guy. I would just like a source. Assumed the weight numbers…
Slightly embarrassed to be asking this, but: why does nobody talk about biopsy. Bought small because the evidence base is early. That is the only defensible position I…
Send the vial, get the number. Third-party purity and identity testing, results published to you regardless of what they say.
Test a vialSponsoredEst. 1998. ISO 9001 and cGMP, 1,500+ staff, 200+ patents. There is a fair chance the vial you are about to send for testing started here. Batch-specific COA as standard.
glbiochem.netwhy does nobody talk about MASH, and I want the answer with the reasoning attached rather than just the conclusion. What this compound is actually being developed for,…
Result first, context after: 8th independent test on JEEP — 97.2% on a claimed 97.0%, and the trend is the interesting part . Everything below is how it was ordered,…
anyone else notice glucagon kicking in around week 47. Full detail below, and I have tried to keep the editorialising out of it. Imaging-derived liver fat fraction is a…
Something I keep coming back to: glucagon co-agonism has its own safety story, stop generalising from tirz. Bought small because the evidence base is early. That is the…
Update, and the title has the headline: anyone else notice survodutide kicking in around week 89. Read the phase 2 hepatic paper properly and the endpoint definitions…
the hepatic fat advice in here is 2 years out of date. Change my mind, genuinely — I have no stake in being right about this. The relevant figures are 2 years, and they…
survodutide is doing more work than we give it credit for. I have gone back and forth on this for months. What this compound is actually being developed for, since the…
Reporting in. week 36 check-in — 12kg down, nausea manageable, one thing confusing me. The numbers the title promised, since a headline without them is worthless: week…
Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.
Independent testing plus vendor-level trend data. Community-funded, unaffiliated.
peptidemeter.comSeveral compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.
Reference